Reckitt Deals Feed OTC Domination Plan
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.
You may also be interested in...
Sales & Earnings In Brief
Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.
Reckitt Reorganizes To Develop Health Care, Emerging Markets
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.